Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.

CONCLUSION: Vaccination against HZ might be cost-effective for ages ranging from 60 to 75 when a threshold of €50,000 per QALY gained would be used, at €20,000 per QALY this might not be the case. Additional information on the duration of vaccine-protection is needed to further optimize cost-effectiveness estimations. PMID: 23306360 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/PubMed/23306360?dopt=Abstract

Source: Vaccine - January 8, 2013 Category: Allergy & Immunology Authors: de Boer PT, Pouwels KB, Cox JM, Hak E, Wilschut JC, Postma MJ Tags: Vaccine Source Type: research